ResMed Cuts a $490 Million Deal to Exit MatrixCare Software

ResMed agreed to sell its MatrixCare software business to Frazier Healthcare Partners for $490 million in cash, the company said Tuesday, July 7, 2026. The deal bundles the MatrixCare platform and three of its related product lines, exits a non-core segment of ResMed’s healthcare software arm, and routes the proceeds into an accelerated share repurchase. The cash price is below the $750 million ResMed paid to acquire MatrixCare alone in 2018. Closing is expected in the first quarter of ResMed’s fiscal year 2027.

The $490 Million Sale ResMed Just Announced

ResMed has entered a definitive agreement to sell MatrixCare to Frazier Healthcare Partners, the company announced July 7, 2026. The buyer is a healthcare-focused private equity firm founded in 1991 and headquartered in Seattle.

A press release on Resmed’s announcement of the MatrixCare sale lays out the dollar terms and the company’s commentary. The unit being sold operates as a standalone business inside ResMed today. Closing is targeted for the first quarter of ResMed’s fiscal 2027, subject to required regulatory approvals. Until then, MatrixCare continues to run as part of ResMed, with no changes to customer service or support on the platform.

• $490 million: all-cash sale price for the MatrixCare business
• $220 million: MatrixCare revenue in fiscal 2026 (preliminary)
• $55 million: MatrixCare non-GAAP operating profit in fiscal 2026 (preliminary)
• 15,000: providers using the MatrixCare platform
• Q1 of ResMed’s fiscal 2027: targeted closing window

What Goes to Frazier and What ResMed Keeps

The “MatrixCare business” ResMed is selling is broader than the MatrixCare platform itself. The press release groups related offerings under that label, using the word “including” before listing the items inside the bundle. Two of ResMed’s separate software units sit outside the sale and remain with the parent.

Items in the deal:

• MatrixCare (the platform)
• Healthcare First
• Citus
• Home health and hospice solutions

Items staying with ResMed:

• Brightree (United States)
• MEDIFOX DAN (Germany)

Each name carries operational context. Brightree serves home medical equipment and pharmacy workflows in the U.S., while MEDIFOX DAN covers Germany.

ResMed’s 8-K filing lays out the same scope as the press release, with the same “MatrixCare business” definition. The platform serves more than 15,000 providers across skilled nursing, senior living, long-term care, life planning, and home health and hospice. None of those providers face service or support changes until the deal closes. A review of the Form 8-K Resmed filed with the SEC confirms the bundled scope and the closing timeline, including the 15,000-provider customer base.

The 2018 Deals That Built the Bundle

ResMed built the bundle now being sold across two acquisitions during 2018. The MatrixCare platform itself cost $750 million, announced in November 2018 and completed in 2019.

HEALTHCAREfirst was the second piece of the bundle, closed in fiscal 2019. The two transactions came together in ResMed’s SaaS portfolio before being consolidated under the “MatrixCare business” label by 2026. The product lines serve distinct operator types across long-term care, skilled nursing, and home health and hospice workflows.

The current $490 million cash exit is below the $750 million ResMed paid for MatrixCare alone. HEALTHCAREfirst, the second deal, carries no separately disclosed sale price inside the bundle. The 2018 transactions added two long-term care software assets to ResMed’s SaaS portfolio. Both lines now exit together under the MatrixCare business label.

HEALTHCAREfirst closed in early fiscal 2019, with MatrixCare announced a few months later in November 2018 and completed the following year. Neither line operated as a separate company inside ResMed at the time of the 2026 sale. The exit closes a chapter of ResMed’s software push, with no separately negotiated value attached to either legacy component as it leaves. ResMed has framed the move as sharpening the company’s 2030 strategy focus on sleep, breathing, and connected care. That 2030 strategy framing first appeared in the same release that announced the divestiture.

Why ResMed Cites ‘potential past inefficiencies’

ResMed’s own filing language names the reason. A disclosure filed Tuesday with the Securities and Exchange Commission said the disposition was necessary to reallocate capital and resources because of potential past inefficiencies or underperformance inside the unit. The wording is ResMed’s own, attributed to the company’s filing rather than outside commentary.

Today’s announcement is about our disciplined approach to portfolio management and our commitment to driving long-term growth.

That line sits inside Chairman and CEO Mick Farrell’s prepared statement attached to the press release. Farrell also framed the move as sharpening ResMed’s focus on “high-growth, scalable opportunities in sleep health, breathing health, and connected home-based healthcare,” language that matches ResMed’s 2030 strategy as described in Tuesday’s release. ResMed reiterated its full fiscal 2026 non-GAAP outlook metrics per the disclosure.

How ResMed Routes the $490 Million Cash

ResMed has flagged two uses for the proceeds. Net cash from the deal will go toward returning capital to shareholders, including through an accelerated share repurchase program. The remainder supports general corporate purposes. Both uses are named in the same 8-K filing that announced the sale.

The mechanics of an accelerated share repurchase differ from a standard buyback. An ASR front-loads the share count retirement by contracting a broker-dealer to deliver shares up front and settling the final quantity later. ResMed’s filing pairs that capital lever with a complementary line item from its recent Noctrix acquisition, which is expected to dilute fiscal 2027 EPS by about $0.20. ResMed did not state which use takes priority under the ASR mechanics. The cash deployment is also open to general corporate purposes as a secondary channel.

ResMed reiterated its fiscal 2026 outlook even with that Noctrix dilution already in the rearview mirror. ResMed also expects transition services agreements with Frazier to largely offset stranded costs in the first year post-closing. The combined picture is a near-term cash lever for per-share earnings, paired with a small operating cost in fiscal 2027.

Who Is Frazier Healthcare Partners

Frazier Healthcare Partners is a Seattle-based private equity firm founded in 1991. The firm focuses exclusively on healthcare, has raised more than $11 billion across private funds and co-investment opportunities, and has invested in more than 200 companies over 35 years. The buyer’s General Partner, Ryan Lucero, put the thesis in the joint release: “Frazier has spent several years evaluating the post-acute care technology sector.” Lucero also described MatrixCare as an established platform with plans to “invest aggressively in product innovation.”

That framing positions Frazier as a product-development buyer rather than a margin buyer. The buyer’s existing healthcare-focused portfolio gives it the operating context to commit capital to a platform ResMed now considers non-core. The two companies have not committed publicly to a separate carve-out plan.

ResMed’s Software Stack After Closing

Closing the deal is not the end of the story for ResMed’s software exposure. The transaction is expected to close during the first quarter of ResMed’s fiscal year 2027, pending required regulatory approvals. Until then, MatrixCare continues to operate as part of ResMed with no changes to customer service or support. The transaction was first announced after the close of business on July 7 on the U.S. East Coast. ResMed has positioned the divestiture as a step toward the company’s 2030 strategy.

What survives the sale is a tighter software footprint. ResMed will retain Brightree in the U.S. and MEDIFOX DAN in Germany, neither of which is part of the transaction. The Residential Care Software (RCS) segment remains the company’s main software growth engine.

Management has said RCS can reaccelerate to “high single-digit percentage year-over-year revenue growth” in fiscal 2027, with operating leverage as the segment scales. That language is forward-looking guidance from ResMed’s 8-K filing rather than an analyst projection. The disclosure also reaffirms ResMed’s fiscal 2026 outlook metrics for gross margin, SG&A, R&D as a percentage of revenue, and the non-GAAP tax rate. Those guiding lines will get another chance to be revised at the next quarterly update.

The Noctrix line item is the per-share story alongside RCS. ResMed closed the Noctrix acquisition recently, and that deal is expected to add about $30 million of revenue in fiscal 2027 while reducing non-GAAP diluted EPS by about $0.20. The next detailed FY27 guidance is due August 6, 2026.

Frequently Asked Questions

What did ResMed agree to sell?

ResMed agreed to sell its MatrixCare software business to Frazier Healthcare Partners for $490 million in cash. The transaction was announced on July 7, 2026. The bundle includes the MatrixCare platform, Healthcare First, Citus, and home health and hospice solutions. Brightree in the U.S. and MEDIFOX DAN in Germany stay with ResMed.

How much is ResMed receiving for MatrixCare?

ResMed will receive $490 million in cash under the terms of the definitive agreement announced July 7, 2026. The press release describes the consideration as all cash. The same disclosure names an accelerated share repurchase and general corporate purposes as the two destinations for the net proceeds.

When will the deal close?

Per ResMed’s release, the deal is targeted to close during the first quarter of fiscal year 2027. Closing remains conditional on regulatory approvals and customary conditions. MatrixCare will continue to operate as part of ResMed until closing, with no break in customer service or support. The release also states ResMed will provide further detail on the financial impact in regulatory filings for Q4 of fiscal 2026.

What will ResMed do with the cash?

ResMed will use net proceeds to return capital to shareholders. The mechanism is an accelerated share repurchase program. The remainder will go toward general corporate purposes. Both uses are named in the same 8-K filing that announced the sale.

What stays in ResMed’s software business after the sale?

ResMed keeps Brightree in the U.S. and MEDIFOX DAN in Germany, both of which sit outside the MatrixCare transaction. The Residential Care Software segment remains the company’s main software growth segment. Management has targeted high single-digit revenue growth for fiscal 2027 in that segment.

Disclaimer: This article covers a corporate divestiture and per-share earnings commentary. It is for informational purposes only and does not constitute investment advice. Forward-looking statements rest on ResMed’s own filing language and may not be realized. Figures are accurate as of publication; readers should consult a qualified financial professional before acting on any information presented here.